Clinical Trial Update: Impact of CES1 Genotype on Metabolism of Methylphenidate [Phase 4]

View source ↗

Summary

Phase 4 trial investigating how CES1 genotype affects methylphenidate metabolism, with study status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Methylphenidate (Methylphenidate)

Snippet

Sponsor: Bispebjerg Hospital | Conditions: Carboxylesterase 1 (CES1) Genotype, CES1 Activity | Phase 4 | Status: COMPLETED